Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Verrica Pharmaceuticals (VRCA) Other Working Capital Changes (2021 - 2025)

Historic Other Working Capital Changes for Verrica Pharmaceuticals (VRCA) over the last 5 years, with Q3 2025 value amounting to $2.4 million.

  • Verrica Pharmaceuticals' Other Working Capital Changes rose 220796.46% to $2.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.2 million, marking a year-over-year decrease of 3783.22%. This contributed to the annual value of $1.1 million for FY2024, which is 29216.35% up from last year.
  • As of Q3 2025, Verrica Pharmaceuticals' Other Working Capital Changes stood at $2.4 million, which was up 220796.46% from -$272000.0 recorded in Q2 2025.
  • Verrica Pharmaceuticals' 5-year Other Working Capital Changes high stood at $2.4 million for Q3 2025, and its period low was -$1.6 million during Q2 2023.
  • In the last 5 years, Verrica Pharmaceuticals' Other Working Capital Changes had a median value of -$113000.0 in 2024 and averaged $182588.2.
  • Its Other Working Capital Changes has fluctuated over the past 5 years, first crashed by 21800.39% in 2023, then surged by 220796.46% in 2025.
  • Over the past 5 years, Verrica Pharmaceuticals' Other Working Capital Changes (Quarter) stood at $1.0 million in 2021, then crashed by 30.97% to $720000.0 in 2022, then tumbled by 41.67% to $420000.0 in 2023, then plummeted by 188.33% to -$371000.0 in 2024, then skyrocketed by 742.05% to $2.4 million in 2025.
  • Its Other Working Capital Changes stands at $2.4 million for Q3 2025, versus -$272000.0 for Q2 2025 and -$546000.0 for Q1 2025.